|Cancer||B acute lymphoblastic leukemia,|
BALR-2 is significantly up-regulated in B-acute lymphoblastic leukemia (B-ALL) patients when compared to normal CD19+ cells. Meanwhile, BALR-2 expression is significantly higher in B-ALL patients that are unresponsive to prednisone as opposed to those responsive. High BALR-2 expression is associated with inferior overall survival. In addition, BALR-2 is a nucleocytoplasmic lncRNA whose expression is regulated by glucocorticoid treatment. Knockdown of BALR-2 results in growth inhibition and increased apoptosis and increased expression of JUN and BIM (1).
|LncRNA||tissue||cancer type||expression level||oncogene/suppress gene||pathway||binding gene/factor||associated gene/factor||proliferation||apoptosis||migration||EMT||invasion||metastasis||prognosis||tag||PMID|
|0||BALR-2||bone marrow||B acute lymphoblastic leukemia||up||onco||JUN-,BIM-||+||-||chemotherapy resistance||25681502|